Table 2.
Univariate and multivariate Cox regression analysis detecting predictors of 1-year mortality.
| 1-year mortality Cox regression analysis | Univariate | Multivariable | ||
| Hazard Ratio (95% CI) | p-value | Hazard Ratio (95% CI) | p-value | |
| Age | 1.028 (0.978–1.082) | 0.278 | ||
| Gender (male) | 1.148 (0.710–1.856) | 0.574 | ||
| Weight | 1.040 (0.988–1.095) | 0.135 | ||
| BMI | 1.122 (0.960–1.312) | 0.149 | ||
| NYHA III | 0.787 (0.411–1.509) | 0.471 | ||
| STS-Score | 1.161 (0.869–1.550) | 0.313 | ||
| Diabetes mellitus | 1.042 (0.595–1.827) | 0.886 | ||
| Arterial Hypertension | 1.163 (0.623–2.172) | 0.635 | ||
| CVD (all) | 1.416 (0.797–2.516) | 0.235 | ||
| CVD - 1 vessel | 1.250 (0.714–2.188) | 0.435 | ||
| CVD - 2 vessels | 0.812 (0.325–2.028) | 0.656 | ||
| CVD - 3 vessels | 0.362 (0.113–1.155) | 0.086 | 0.669 (0.075–5.971) | 0.719 |
| Myocardial infarction | 0.965 (0.236–3.942) | 0.960 | ||
| Atrial fibrillation | 1.376 (0.844–2.242) | 0.200 | ||
| Pacemaker | 1.573 (0.719–3.443) | 0.257 | ||
| Malignancy | 0.866 (0.473–1.586) | 0.641 | ||
| Stroke | 1.028 (0.374–2.825) | 0.957 | ||
| pAVK | 0.690 (0.217–2.198) | 0.531 | ||
| COPD | 1.506 (0.746–3.041) | 0.253 | ||
| LVEF | 0.997 (0.975–1.019) | 0.799 | ||
| LVEDD | 0.940 (0.619–1.428) | 0.772 | ||
| IVSd | 1.158 (1.068–1.257) | 0.001 | 0.962 (0.662–1.397) | 0.838 |
| AV Vmax | 0.971 (0.833–1.132) | 0.706 | ||
| AV dpmean | 1.008 (0.989–1.028) | 0.403 | ||
| AV dpmax | 1.002 (0.990–1.015) | 0.747 | ||
| TAPSE | 0.947 (0.832–1.078) | 0.412 | ||
| sPAP | 1.020 (1.004–1.036) | 0.015 | 1.024 (0.985–1.065) | 0.238 |
| AVI II° | 0.648 (0.307–1.366) | 0.254 | ||
| MVI II° | 0.563 (0.288–1.103) | 0.094 | 0.331 (0.056–1.962) | 0.223 |
| TVI II° | 0.588 (0.268–1.289) | 0.185 | ||
| Creatinine | 1.403 (0.738–2.666) | 0.301 | ||
| BNP | 0.996 (0.780–1.272) | 0.975 | ||
| cTnI | 1.453 (1.099–1.921) | 0.009 | 1.598 (1.174–2.174) | 0.003 |
| Hkt | 0.981 (0.935–1.030) | 0.445 | ||
| Hb | 0.967 (0.843–1.108) | 0.626 | ||
| CK | 0.970 (0.746–1.263) | 0.823 | ||
| sST2 | 1.178 (0.935–1.483) | 0.164 | ||
| GDF-15 | 1.082 (0.854–1.372) | 0.513 | ||
| H-FABP | 1.008 (0.795–1.277) | 0.948 | ||
| IGF-BP2 | 1.473 (1.107–1.960) | 0.008 | 1.550 (1.122–2.140) | 0.008 |
| suPAR | 0.905 (0.694–1.180) | 0.461 |
BMI, body mass index; CVD, cardiovascular disease; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; IVSd, interventricular septal thickness at diastole; AV Vmax, maximal velocity over aortic valve; AV dpmean, mean pressure gradient over aortic valve; AV dpmax, maximal pressure gradient over aortic valve; TAPSE, tricuspid annular plane systolic excursion; sPAP, systolic pulmonary artery pressure; AVI, aortic valve insufficiency; MVI, mitral valve insufficiency; TVI, tricuspid valve insufficiency; BNP, brain natriuretic peptide; cTnI, cardiac Troponin I; CK, creatine kinase; sST2, soluble suppression of tumorigenicity-2; GDF-15, growth/fifferentiation of factor-15; H-FABP, heart-type fatty-acid binding protein; IGF-BP2, insulin like growth factor binding protein 2; suPAR, soluble urokinase-type plasminogen activator receptor.